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MaHeart failure patients are classiﬁed by ejection fraction (EF) into distinct groups: heart failure with preserved ejection
fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF). Although patients with heart failure commonly
have multiple comorbidities that complicate management and may adversely affect outcomes, their role in the HFpEF
and HFrEF groups is not well-characterized. This review summarizes the role of noncardiac comorbidities in patients with
HFpEF versus HFrEF, emphasizing prevalence, underlying pathophysiologic mechanisms, and outcomes. Pulmonary
disease, diabetes mellitus, anemia, and obesity tend to be more prevalent in HFpEF patients, but renal disease and sleep-
disordered breathing burdens are similar. These comorbidities similarly increase morbidity and mortality risk in HFpEF and
HFrEF patients. Common pathophysiologic mechanisms include systemic and endomyocardial inﬂammation with ﬁbrosis.
We also discuss implications for clinical care and future HF clinical trial design. The basis for this review was discussions
between scientists, clinical trialists, and regulatory representatives at the 10th Global CardioVascular Clinical Trialists
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ABBR EV I A T I ON S
AND ACRONYMS
COPD = chronic obstructive
pulmonary disease
CPAP = continuous positive
airway pressure
CSA = central sleep apnea
DM = diabetes mellitus
EF = ejection fraction
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
LV = left ventricular
OSA = obstructive sleep apnea
RAAS = renin-angiotensin-
aldosterone systems
SDB = sleep-disordered
breathing
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2282P atients with heart failure (HF) oftenhave multiple concomitant diseasesthat complicate management and
may adversely affect outcomes (1,2). Recent
data from the Centers for Medicare &
Medicaid Services demonstrate that 55% of
Medicare patients coded as having HF
have $5 chronic comorbidities (3). Data
from the European Society of Cardiology
Heart Failure Pilot Survey indicate that the
majority of patients with chronic HF (74%)
had at least 1 comorbidity, the most common
of which are renal disease, anemia, and dia-
betes mellitus (DM) (4). In general, more
than one-quarter of HF patients have comor-
bid pulmonary or renal dysfunction, both of
which are associated with increased mor-
bidity and mortality in the overall HF popula-
tion (5–8). Patients are commonly classiﬁedaccording to ejection fraction (EF) into heart failure
with preserved ejection fraction (HFpEF) (EF $50%)
or heart failure with reduced ejection fraction (HFrEF)
(EF <50%). The role of comorbidities has not been
well characterized in these HF types. The present re-
view summarizes the role of noncardiac comorbidities
in patients with HFpEF versus HFrEF, with particular
emphasis on prevalence, underlying pathophysiolog-
ical mechanisms, and association with outcomes. We
focused on chronic obstructive pulmonary disease
(COPD), anemia, DM, renal disease, sleep-disordered
breathing (SDB), and obesity. We brieﬂy discuss other
noncardiac comorbidities, including frailty and
arthritis, and highlight the need for future research
on these topics, as well as on depression, myopathy,
and liver disease. The implications of these data for
clinical care and for the design of future HF clinical
trials are also described. Cardiac comorbidities
(including hypertension, coronary artery disease,
and atrial ﬁbrillation) were recently discussed else-
where (9) and are beyond the scope of the present re-
view. This review is on the basis of discussions
between scientists, clinical trialists, and regulatory
and industry representatives at the 10th Global Car-
dioVascular Clinical Trialists Forum held in Paris,
France, on December 6, 2013.
METHODS
To identify additional relevant published data not
discussed at the 10th Global CardioVascular Clinical
Trialists, we searched MEDLINE (via PubMed) from
January 1994 to July 2014 (the Online Appendix pre-
sents the full search strategy). We used Medical
Subject Headings and key words, focusing on themost relevant terms for this topic. We manually
searched reference lists of pertinent reviews, in-
cluding studies and background data to ﬁnd any
relevant citations that our searches might have
missed. We imported all citations into an EndNote X7
database. One reviewer (J.P.K.) screened and evalu-
ated the retrieved records to select relevant studies.
To focus on studies with representative patient sam-
ples, our search strategy required that publications
included >500 patients and reported data from mul-
tiple sites. Given that entry criteria for clinical trials
tend to exclude those with signiﬁcant comorbidities,
we focused on data from large HF registries and
cohort studies. We required that the primary papers
or supplemental materials include data on noncardiac
comorbidities of interest.
In general, the prevalence of comorbidities was
high across all studies, as demonstrated in the 3
largest U.S. HF registries (2,10,11), as well as ambu-
latory HF populations in the United States (12,13),
as discussed later in this review. Other world regions
demonstrated ﬁndings similar to those seen in the
United States (14–16). Table 1 presents comorbidity
prevalence data from several representative HF reg-
istries and epidemiological cohorts.
RESULTS
HFPEF VERSUS HFREF: DEMOGRAPHIC DIFFERENCES.
Overall, the data suggest that patients hospitalized
with HFpEF tend to be 4 to 8 years older than those
with HFrEF and are more often female (Table 1).
These observations are supported by an analysis from
the Framingham Heart Study, which demonstrated
that female sex was independently associated with a
>2-fold increased risk for HFpEF versus HFrEF (17).
Increasing age predicts both HFpEF and HFrEF, but
the risk is signiﬁcantly greater for HFpEF (18). The sex
differences in HF phenotype seem largely due to
increased HFrEF in men related to previous myocar-
dial infarction (18). Another explanation for these
ﬁndings relates to a differential response to hyper-
tension in men versus women. Men tend to develop
eccentric left ventricular (LV) hypertrophy in
response to hypertension, whereas women tend to
develop concentric LV hypertrophy (19). Studies also
found that African-American subjects have HFpEF
less often than they have HFrEF (2,10,11). These ﬁnd-
ings are counterintuitive due to the high prevalence of
hypertension and LV hypertrophy in this population.
The speciﬁc reasons for these observations are un-
known and require further investigation, but they
may be related, in part, to ascertainment of the HFpEF
diagnosis. It is unclear whether these ﬁndings are due
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2283to increased complexity in HFpEF detection, particu-
larly in regions where echocardiography or natriuretic
peptides are less available. In general, there is a rela-
tive paucity of large-scale comparative data regarding
the burden of comorbidities in racial and ethnic
minority populations with HF (20).
OUTCOMES OVERVIEW. Evidence regarding the
outcomes of HFpEF versus HFrEF patients varied in
different populations, but overall, the data suggest
that HFpEF is associated with substantial morbidity
and mortality that approaches or matches that of
HFrEF (13,21,22). Interestingly, 1 recent analysis
demonstrated that when similar B-type natriuretic
peptide levels were compared across EF values, the
risk for adverse outcomes was similar in HFpEF and
HFrEF patients (23). The overall incidence of hospital
admission is similar between the 2 groups, but HFpEF
patients have a higher incidence of non-HF hospital-
izations, whereas HFrEF patients have a higher in-
cidence of HF hospitalizations (24). Comorbidities,
such as COPD, renal disease, and DM, are strongly
associated with adverse outcomes in HF patients (25).
HFpEF is not merely a disease of old age and multiple
comorbidities but is a distinct entity associated with
poor prognosis and severe cardiovascular dysfunction
(26,27). However, few studies have explored the dif-
ferential association between comorbidities and out-
comes in HFrEF and HFpEF patients (24,28–30). In
general, the increased risk for morbidity and mortal-
ity associated with these comorbidities is similar in
those with HFpEF and HFrEF.
PATHOPHYSIOLOGY. The Central Illustration pre-
sents pathways linking several comorbidities to dis-
ease progression in both HFpEF and HFrEF. These
comorbidities interrelate by several common mecha-
nisms, including inﬂammation and activation of the
sympathetic and renin-angiotensin-aldosterone sys-
tems (RAAS), as discussed later in this review.
COMORBIDITIES IN HFrEF VERSUS HFpEF PATIENTS:
PREVALENCE, OUTCOMES, AND TREATMENTS. Chron ic
obstruct ive pulmonary d isease . COPD occurs in
approximately one-third of HF patients, with a
slightly higher prevalence in HFpEF patients
compared with HFrEF patients (5); the speciﬁc ratio-
nale for the increased prevalence in HFpEF patients is
unclear. Comorbidities such as COPD were suggested
to induce a proinﬂammatory state that causes endo-
thelial and cardiomyocyte dysfunction, with resul-
tant myocardial ﬁbrosis and clinical HFpEF (31).
Ongoing smoking was also identiﬁed as an in-
dependent predictor of HFpEF, but not HFrEF, in
epidemiological studies (18), which supports the in-
ﬂammatory hypothesis. However, further research is
HEART FAILURE SPECIFICSBIDIRECTIONAL IMPACT ON DISEASE PROGRESSION
Sodium and fluid retention; anemia; inflammation; RAAS and sympathetic activation
Renal
dysfunction
Hypoxia; systemic inflammation; sympathetic activation; arrhythmias; hypertension (pulmonary and
 systemic); RV dysfunction; worsening congestion 
Rostral fluid movement may worsen pharyngeal obstruction; instability of ventilatory control system
Sleep-
disordered 
breathing
Chronic 
obstructive 
pulmonary 
disease
COMORBIDITY
Diabetic cardiomyopathy; mitochondrial dysfunction; abnormal calcium homeostasis; oxidative stress;
renin-angiotensin-aldosterone system (RAAS) activation; atherosclerosis; coronary artery disease
Incident and worsening diabetes mellitus via sympathetic and RAAS activation
Adverse LV remodeling; adverse cardiorenal effects; increased neurohormonal and inflammatory 
cytokines
Inflammation; hemodilution; renal dysfunction; metabolic abnormalities exacerbate
Inflammation; hypoxia; parenchymal changes; airflow limitation, leading to pulmonary congestion; 
abnormal left ventricular (LV) diastolic filling; inhaled beta-agonist cardiovascular effects
Elevated LV end-diastolic pressure and beta-blocker use may compromise lung function
Fatigue and dyspnea may limit activity; spectrum of metabolic disorders including nutritional deficiencies
Inflammation; reduced physical activity and deconditioning; hypertension; metabolic syndrome;
diabetes mellitus
More prevalent in preserved 
ejection fraction (HFpEF), 
compared to reduced (HFrEF)
Higher mortality risk in HFpEF
More prevalent in HFpEF
Similar increased risk for 
mortality in both groups
More prevalent in HFpEF
Similar increased risk for 
mortality in both groups
Similar prevalence
in both groups
Similar increased risk for 
mortality in both groups
More prevalent in HFpEF
Obesity paradox; potential
 for a U-shaped association 
with mortality
Similar prevalence
in both groups
Unknown mortality differential 
associated with HFpEF vs. HFrEF
Diabetes
Obesity
Anemia
Cardiorenal syndrome through low cardiac output;
accelerated atherosclerosis; inflammation; increased venous pressure
Mentz, R.J. et al. J Am Coll Cardiol. 2014; 64(21):2281–93.
CENTRAL ILLUSTRATION Associations Between HFpEF and HFrEF, With Comorbidities
Pathways linking several common comorbidities to disease progression in both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced
ejection fraction (HFrEF) are presented, and factors exacerbating other comorbid conditions are highlighted. These comorbidities are interrelated by several common
mechanisms, including inﬂammation and worsening congestion, as well as by sympathetic and renin-angiotensin-aldosterone system activation. Heart failure inﬂuences
each of the comorbidities, demonstrating the bidirectional association. CV ¼ cardiovascular; LV ¼ left ventricular; RAAS ¼ renin-angiotensin-aldosterone system; RV ¼
right ventricular.
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2284needed because smoking would also be expected to
increase risk for coronary events and resultant
ischemic cardiomyopathy with reduced EF. An alter-
native explanation for the close association between
COPD and HFpEF involves coupling between
impaired LV ﬁlling and pulmonary venous changes
due to lung parenchymal abnormalities (32). More-
over, HF may result in pulmonary function changes
and patient symptoms that mimic COPD. Because
patients with preserved EF do not have the alterna-
tive diagnosis of low EF, they may be more likely to
receive a COPD diagnosis as an explanation for dys-
pnea (33,34). Despite the potential for bias related to
increased COPD diagnosis in HFpEF patients, the
consistent observation of increased COPD prevalence
in HFpEF patients suggests that concomitant pulmo-
nary and cardiac dysfunction may be particularly
important in the preserved EF group.The primary effect of COPD seems to be increased
noncardiovascular mortality during HF hospitaliza-
tion (6), with similar outcomes in the early period
after discharge (35). COPD is associated with in-
creased long-term morbidity (36) and mortality (25).
HF patients with COPD are less likely to receive beta-
blockers compared with those without COPD (36),
possibly due to clinicians’ concerns about precipi-
tating bronchoconstriction (33,37,38). The over-
lapping symptom of dyspnea with both diseases may
lead to misapplication of therapy. Given the discor-
dant beta-receptor effects of the different disease
treatments, a patient’s symptoms and outcome could
be adversely affected by the treatment of the co-
morbid disease. HF patients with COPD also tend to
have lower blood pressure, higher creatinine levels,
and underuse of angiotensin-converting enzyme in-
hibitors and mineralocorticoid receptor antagonists
J A C C V O L . 6 4 , N O . 2 1 , 2 0 1 4 Mentz et al.
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2285(6,35). These characteristics likely contribute to the
increased mortality risk associated with COPD in pa-
tients with HF.
In a recent analysis of the differential association
between comorbidities and outcomes in HFrEF and
HFpEF patients, COPD was the only comorbidity for
which there was a signiﬁcant interaction (p ¼ 0.01)
with EF group and outcomes. COPD contributed to a
higher hazard for mortality in patients with HFpEF
compared with HFrEF (24). Notably, COPD was an
independent predictor of mortality in both groups.
These between-group differences are supported by
ﬁndings from another small study in which COPD
was highly predictive of death in those with HFpEF
but not HFrEF (39). Data from the Framingham Heart
Study support a potential causal role between airﬂow
limitation and HFpEF but not HFrEF (40). The link
between even mild airﬂow limitation and abnormal
LV diastolic ﬁlling (41) may explain, in part, the
stronger association between COPD and HFpEF.
COPD treatment recommendations focus on pre-
vention, including vaccinations and smoking cessa-
tion. Pending randomized trial data, chronic therapy
with long-acting anticholinergic agents is recom-
mended preferentially over the use of inhaled beta-
agonists (37). Early intervention in the setting of
exacerbations and a multidisciplinary approach may
be indicated to balance therapies for both diseases
(33). Intravascular volume management may repre-
sent an area of particular focus, with the goal of mini-
mizing LV ﬁlling pressures and pulmonary interstitial
ﬂuid, even in the presence of agents that adversely
affect volume status, such as corticosteroids. With
respect to beta-blocker use, there is a mechanistic
rationale to consider the preferential use of car-
dioselective agents, such as metoprolol succinate
or bisoprolol, rather than carvedilol (37). Evidence
from several small studies supports this approach
(38,42,43). However, observational studies suggested
that there is no differential beneﬁt with cardio-
selective agents compared with noncardioselective
agents (36,44). Thus, adequately powered prospective
studies are needed to determine the optimal beta-
blocker approach in HF patients with COPD.
Anemia . Comorbid anemia is more frequent in
HFpEF patients than in HFrEF patients. Prevalence
reports vary depending on the speciﬁc anemia deﬁ-
nition used, but the trends are comparable. Con-
temporary studies tend to use the World Health
Organization classiﬁcation of anemia as hemoglobin
<13 g/dl in men and <12 g/dl in women (24). In the Get
With The Guidelines Registry, there was an associa-
tion between higher EF and increased prevalence of
anemia (11). The prevalence of anemia was 22% inpatients with an EF $50%, 20% with EF 40% to 49%,
and 14% with EF <40%, and there were also sex-
speciﬁc differences (45). The prevalence of anemia
tended to be higher in women in the setting of either
reduced or preserved EF. These ﬁndings are sup-
ported by an analysis from the OPTIMIZE-HF (Orga-
nized Program to Initiate Lifesaving Treatment in
Patients with Heart Failure), which showed that HF
patients (46) with low hemoglobin levels were older,
more often female, and had preserved systolic func-
tion. In the CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity)
program, lower hemoglobin was associated with
higher EF (47). Furthermore, female sex, DM, and
worse renal function were several of the strongest
predictors of anemia. These ﬁndings suggest a com-
plex relationship between EF and anemia that likely
involves inﬂammation, hemodilution, bone marrow
deﬁciency, nutritional and metabolic factors, and
nephropathy (48). In addition, studies suggest that
anemia may increase cardiac output and reduce
systemic resistance through nitric oxide–mediated
vasodilation (49–51).
Anemia is associated with increased morbidity and
mortality in HF patients (52–55). Potential explana-
tions include adverse LV remodeling effects (56),
increased neurohormonal and inﬂammatory cyto-
kines (49), adverse cardiorenal effects (57), and the
association with poor nutritional status (47). Multiple
previous studies have reported that there is no inter-
action between EF and outcomes related to anemia
status. For instance, in 1 study, anemia was associated
with an w25% increased mortality risk in HFrEF and
HFpEF patients (24). Similarly, Felker et al. (28)
demonstrated that anemia was independently asso-
ciated with mortality, and there was no evidence of an
interaction with systolic function. A recent analysis
from the SENIORS (Study of the Effects of Nebivolol
Intervention on Outcomes and Rehospitalization in
Seniors with Heart Failure) trial, which included HF
patients irrespective of LVEF, extends these results to
morbidity endpoints (58). Anemic patients were at
increased risk for the composite of all-cause mortality
or cardiovascular hospitalization and mortality, or
HF hospitalization, regardless of underlying HFrEF
or HFpEF. Notably, the overall representation of pa-
tients with LVEF >50% in SENIORS was modest. The
inability to demonstrate a differential relationship
between anemia and outcomes in those with HFpEF
versus HFrEF may be related, in part, to the number of
different etiologies for anemia.
Because of the neutral results of recent trials tar-
geting anemia with erythropoietin-stimulating agents
in HFrEF patients (59), the optimal treatment of
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Given iron deﬁciency’s relation to anemia status and
its potential as a treatable target, this area is of
particular interest (60). The prevalence of iron deﬁ-
ciency in HF patients is even greater than the preva-
lence of clinical anemia. Furthermore, iron deﬁciency
may affect outcomes in HFpEF and HFrEF indepen-
dent of anemia (61). Iron deﬁciency leads to wors-
ening HF symptoms, HF progression, and poor
outcomes (62). Ongoing and future studies will
explore the effect of iron replacement in both HFpEF
and HFrEF patients.
Diabetes mel l i tus . Registry and observational data
consistently report the presence of DM in w40% of
HFrEF patients versus 45% of HFpEF patients
(2,10,24). DM is associated with the development of
myocardial dysfunction, even in the absence of sig-
niﬁcant coronary artery disease or hypertension (i.e.,
diabetic cardiomyopathy) (63). Myocardial changes
result from insulin resistance and hyperglycemia
through various mechanisms, including increased
free fatty acid concentration, mitochondrial
dysfunction, abnormal calcium homeostasis, RAAS
activation, oxidative stress, and advanced glycation
end products (63,64). Development of systolic
dysfunction may be preceded by myocardial ﬁbrosis
and collagen deposition, resulting in diastolic
dysfunction (65,66). Importantly, the relationship
between DM and HF seems bidirectional, with HF also
increasing the risk for subsequent DM (67). The
mechanisms underlying the effect of HF on incident
DM or on DM progression are not completely known,
but they may involve sympathetic and RAAS activa-
tion, with subsequent lipolysis and increased cyto-
kine production (68,69).
DM is associated with increased morbidity and
mortality in patients with chronic HF (29,70), but its
inﬂuence as a predictor of long-term outcomes after
HF hospitalization is less well deﬁned. Several acute
HF registries have suggested that DM patients are at
increased risk for mortality (71,72). However, in the
OPTIMIZE-HF registry, DM patients were at increased
short-term risk for rehospitalization but at similar risk
for in-hospital and short-term mortality (73). Simi-
larly, in the EVEREST (Efﬁcacy of Vasopressin
Antagonism in Heart Failure Outcome Study with
Tolvaptan) study, DM was associated with increased
HF rehospitalization but not with all-cause mortality
(74). DM may complicate the clinical course of HF
patients through various mechanisms, including
electrolyte disturbances, increased infection risk, and
altered medication absorption, as well as through
ischemia and other direct adverse effects on the
myocardium (1).The impact of DM in patients with HFpEF versus
HFrEF is not well deﬁned. One recent analysis
demonstrated that the point estimate of hazard for
mortality associated with DM was greater in HFrEF
patients than in HFpEF patients, but formal statistical
testing did not ﬁnd an interaction between the DM
and EF groups (24). An analysis from CHARM
demonstrated that DM was associated with similarly
increased risk for mortality in HFpEF and HFrEF pa-
tients (29). In contrast, DM was associated with
increased cardiovascular death or HF hospitalization
in HFpEF patients compared with HFrEF patients.
This difference was due to an increased risk for HF
hospitalization associated with DM in HFpEF pa-
tients. However, in an analysis from OPTIMIZE-HF,
HFpEF patients with DM were not at increased risk
for 60- to 90-day mortality or rehospitalization, in
contrast to the increased risk associated with DM in
HFrEF patients (interaction p ¼ 0.0012) (73). Thus, the
impact of DM on outcomes in different EF groups is
not entirely clear, but it may be related to predomi-
nant effects on long-term HF rehospitalization, rather
than mortality. It is also possible that there are dif-
ferential effects in patients who had a recent HF
hospitalization compared with those who have
chronic, stable HF.
The optimal treatment of comorbid diabetes in HF
patients is unclear. Several classes of antidiabetic
agents such as thiazolidinediones and dipeptidyl
peptidase 4 inhibitors were shown to be associated
with increased risk of HF (75,76). Alternatively,
ongoing studies are investigating whether antidia-
betic agents, such as glucagon-like peptide-1 ago-
nists, may improve outcomes in HF patients via
beneﬁts on cardiac metabolism (FIGHT [Functional
Impact of GLP-1 for Heart Failure Treatment;
NCT01800968]). Despite metformin’s package label
warning about its use in patients with HF, the
occurrence of lactic acidosis is exceedingly low in
clinical practice, and recent observational data (77)
suggest possible beneﬁts on clinical outcomes asso-
ciated with its use in HF. Ongoing large-scale diabetes
studies investigating cardiovascular outcomes, in-
cluding HF, will inform the management of DM in
these patients (EXSCEL [Exenatide Study of Cardio-
vascular Event Lowering Trial; NCT01144338).
Pending the results of these studies, the treatment of
DM in patients with HF should preferentially include
agents with favorable safety proﬁles in patients with
cardiovascular disease (78). Given the key roles of
obesity and metabolic syndrome in the underlying
pathophysiology (79), they may also represent
important targets in DM patients with HF, particularly
those with HFpEF.
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2287Renal dysfunct ion . Registry data indicate a similar
extent of renal insufﬁciency in HF patients across the
EF spectrum (2,11). The reports vary signiﬁcantly in
different datasets, depending on the speciﬁc criteria
used, but the ﬁgures are similar in patients with
HFrEF and HFpEF. The interdependence of heart and
kidney dysfunction is captured by the recently
described “cardiorenal syndrome” (7,80). Renal
dysfunction may worsen HF through multiple mech-
anisms, including increased sodium and ﬂuid reten-
tion, anemia, inﬂammation, and uremic toxins, as
well as RAAS and sympathetic activation. A recent
analysis found a signiﬁcant association between
urinary markers of renal dysfunction and the risk for
new-onset HFpEF but not HFrEF (81). Conversely, HF
may lead to renal dysfunction and cardiorenal syn-
drome through mechanisms related to low cardiac
output, accelerated atherosclerosis, inﬂammation,
and increased venous pressure. The multitude of
mechanisms that may result in renal dysfunction
could, in part, explain its similar prevalence in HFpEF
and HFrEF patients. For instance, HFpEF patients
may be more likely to have underlying renal
dysfunction related to diabetic nephropathy, whereas
atherosclerosis may contribute to renal function
changes in patients with HFrEF due to ischemic/
nephrosclerotic etiology (16).
Renal dysfunction is an established risk factor for
adverse events in patients with HF (82,83). ADHERE
(Acute Decompensated Heart Failure National Regis-
try) revealed that more than one-half of acute HF
patients had at least moderate renal insufﬁciency on
admission, which was associated with increased
mortality (84). Importantly, recent data have
demonstrated that the association between renal
dysfunction and poor outcomes is complex. For
instance, transient worsening renal function during
acute HF hospitalization may not affect post-
discharge outcomes (85,86), and aggressive ﬂuid
removal leading to hemoconcentration may be asso-
ciated with lower mortality, despite evidence of
worsening renal function (86). Thus, the underlying
cause and trajectory of renal dysfunction could play a
role in determining the impact on subsequent out-
comes. Notably, HF patients with renal dysfunction
tend to be older, with lower blood pressure and
higher plasma B-type natriuretic peptide levels (87).
Kidney disease also affects guideline-directed medi-
cal therapy in HFrEF patients due to concerns about
worsening glomerular ﬁltration rate and hyper-
kalemia (87). In addition to similar prevalence in
HFrEF and HFpEF patients, the increased risk asso-
ciated with the comorbidity is similar in both patient
groups. Ather et al. (24) demonstrated that renalinsufﬁciency was associated with an w25% to 30%
increase in mortality. In a community-based HF pa-
tient cohort, worsening estimated glomerular ﬁltra-
tion rate was associated with a graded increase in the
risk for death and hospitalization, with similar ﬁnd-
ings in those with HFpEF and HFrEF (30).
The implications of renal insufﬁciency for the
treatment of HFpEF and HFrEF patients are several-
fold. First, despite concerns related to hyper-
kalemia, therapies such as angiotensin-converting
enzyme inhibitors should be initiated and moni-
tored in accordance with current guidelines (88,89).
Recent data suggest that worsening renal function
while on an RAAS inhibitor has a better prognosis
than with placebo, suggesting that a RAAS inhibitor
should not necessarily be discontinued in patients
who develop worsening renal function (90). Renal
insufﬁciency may also have important implications
related to the management of volume status and the
titration of diuretic therapies. For instance, with more
severe underlying renal disease, it may be necessary
to consider alternative loop diuretic agents, such as
torsemide, or the addition of a thiazide diuretic
agent (91).
Sleep-d isordered breath ing . In recent years, the
prevalence and impact of SDB in HF patients have
been increasingly recognized, and multiple ongoing
registries are collecting data in this regard (SchlaHF
[Sleep-Disordered Breathing in Heart Failure—The
SchlaHF-Registry; NCT01500759]). Previous studies
have found that SDB is prevalent in both those with
HFpEF and those with HFrEF, occurring in upward of
50% to 80% of patients (92–94). Two primary types of
SDB occur and may coexist in HF patients: obstruc-
tive sleep apnea (OSA) and central sleep apnea
(CSA). HFpEF patients tend to more often have OSA,
compared with HFrEF patients who tend to have
CSA to a greater extent (95). Women with HF are less
likely to have SDB compared with men, and its
severity may be lower (96). Risk factors for the
development of both types of SDB in HF patients
include male sex and increased age (97,98). Elevated
body mass index is an additional risk factor for OSA,
whereas severe LV impairment and atrial ﬁbrillation
increase the likelihood of CSA (97,99). SDB is proin-
ﬂammatory, with effects on oxidative stress and
sympathetic activation (94).
SDB has been associated with increased morbidity
and mortality in the general population (100–102);
however, its impact on HF patient outcomes is less
well deﬁned. The majority of studies in HF patients
focused on HFrEF patients, who had SDB that was an
independent predictor of cardiac readmission (103).
In 164 patients with chronic stable HFrEF, untreated
TABLE 2 Treatments for Comorbidities in Patients With HFpEF and Those With HFrEF
Recommendations/Comments
Chronic obstructive
pulmonary disease
Emphasis on prevention (e.g., vaccinations, smoking cessation)
Consider preferential use of inhaled anticholinergics over beta-agonists
pending deﬁnitive clinical trials
Early intervention in the setting of exacerbations of either disease
Multidisciplinary management with cardiology and pulmonary
Volume optimization may be particularly important in these patients
Preferential use of cardioselective beta-blockers (metoprolol succinate
or bisoprolol) pending additional prospective trials
Anemia Thorough evaluation and treatment of underlying cause(s) of anemia
Management of contributing factors such as renal insufﬁciency
and diabetes
Broad application of erythropoietin-stimulating agents in HFrEF is not
supported by previous studies
Iron deﬁciency may represent a relevant treatment target
Diabetes mellitus Avoid diabetic therapies that have been associated with increased risk
of heart failure (e.g., TZDs, DPP-4 inhibitors)
Careful monitoring for other diabetic agents (e.g., metformin) in the
setting of heart failure decompensation and renal dysfunction
Preferential use of metformin may be reasonable pending prospective
trials given observational data suggesting beneﬁts for clinical
outcomes
Renal dysfunction Appropriate initiation of ACE inhibitors/ARBs and MRAs, as able, with
careful clinical monitoring
Volume status may be a key target of intervention
Alternative loop diuretic agents (e.g., torsemide) may be indicated
Multidisciplinary management with cardiology and nephrology
Sleep-disordered
breathing
CPAP or ASV device therapy may provide beneﬁts on clinical status
(outcomes beneﬁt undeﬁned)
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; ASV ¼ adaptive servo-ventilation;
COPD ¼ chronic obstructive pulmonary disease; CPAP ¼ continuous positive airway pressure; DPP-4 ¼ dipep-
tidyl peptidase 4; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced
ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; TZDs ¼ thiazolidinediones.
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multivariable analysis (104). CSA was also shown to
be a predictor of mortality in HFrEF (105). However,
not all studies demonstrated a relationship between
SDB and outcomes in HFrEF patients (106,107).
To our knowledge, no previous studies scrutinized
a differential association between SDB and outcomes
in HFrEF versus HFpEF patients. Studies to date in
HFpEF patients generally assessed <200 patients,
with the emphasis on describing prevalence and pa-
tient characteristics, rather than outcomes (95,108).
Thus, future research is needed to explore the impact
of SDB on outcomes in HFpEF. SDB may represent a
particularly important comorbidity in HFpEF pa-
tients, given the high prevalence of obesity in this
patient population.
The primary treatment for OSA is nocturnal con-
tinuous positive airway pressure (CPAP). Although
observational studies in HF patients with OSA sug-
gested potential beneﬁts with CPAP on clinical out-
comes (109), large-scale randomized studies are
needed. The role of CPAP in CSA is even less well
deﬁned. The largest randomized, prospective studyof HF patients with CSA (N ¼ 258) found no survival
beneﬁt with CPAP, despite improvements in EF
and functional status (110). Compared with CPAP
devices, minute ventilation-targeted adaptive servo-
ventilation may treat both CSA and OSA with
improved tolerability. Studies have demonstrated
beneﬁts on surrogate endpoints with adaptive servo-
ventilation in HF patients (111,112). Survival beneﬁts
with adaptive servo-ventilation in HF patients have
not been demonstrated, and randomized trials are
ongoing (SERVE-HF [Treatment of Predominant
Central Sleep Apnoea by Adaptive Servo Ventilation
in Patients With Heart Failure; NCT00733343] and
CAT-HF [Cardiovascular Improvements With MV ASV
Therapy in Heart Failure; NCT01953874]).
OTHER COMORBIDITIES. Obesity is common in the
general HF population, with a higher prevalence in
HFpEF patients (Table 1). Although increased body
weight has been associated with improved outcomes
in cardiovascular disease populations (113), recent
reports discussed a balanced reappraisal of this
obesity paradox (114,115). A higher weight may be
associated with better outcomes compared with HF
patients with cardiac cachexia and/or nutritional de-
ﬁciencies. Potential mechanisms for improved out-
comes associated with obesity include increased
metabolic reserve and lipoprotein pools to serve as
scavengers for circulating endotoxins. However, the
associations between obesity and metabolic syn-
drome, glucose intolerance, and diabetes are likely to
explain, in part, the link between increased body
weight and adverse events in certain circumstances.
For instance, a recent study in 4,109 HFpEF patients
found a U-shaped relationship between body mass
index and adverse clinical events. Body mass
indices <23.5 or $35 kg/m2 were each associated with
a 27% increase in death or cardiovascular hospitali-
zation, compared with the reference group body mass
index of 26.5 to 30.9 kg/m2 (116). Future studies are
needed to assess whether treatment strategies tar-
geting appropriate weight gain or weight reduction
can improve outcomes in both HFpEF and HFrEF
patients.
Additional important comorbidities in HF patients
include frailty and arthritis (117). Frailty, limited
mobility, and fall risk are increasingly recognized as
important predictors of outcomes in HF patients
(118). Osteoarthritis is of particular interest, given the
inﬂammatory hypothesis linking comorbidities and
adverse cardiovascular outcomes (119). Furthermore,
nonsteroidal anti-inﬂammatory drug treatment for
osteoarthritis may have direct consequences on ﬂuid
retention and the precipitation of acute HF. There is a
need for future research on these topics as well as on
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to implications for the management and outcomes of
HFpEF and HFrEF patients.
CLINICAL PRACTICE AND IMPLICATIONS FOR
FUTURE TRIAL DESIGN. Although the presence of
multiple comorbid diseases is almost universal in
clinical practice, HF guidelines provide little discus-
sion of this, and the evidence base is sparse and
mostly observational. Compared with HFrEF patients,
those with HFpEF tend to have an increased burden of
COPD, DM, and anemia, which are associated with
increased morbidity and mortality. Because the
development of novel HF therapies has slowed in
recent years, and most contemporary HF trials haveEncourage 
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these conditions are closely interrelated and may
potentiate each other, targeting comorbidities may
represent an important component in the compre-
hensive management of HF patients.
Another major clinical implication of these data
relates to polypharmacy, particularly in the elderly,
in whom the prevalence of HF rises sharply. Elderly
patients may exhibit variable responses to standard
medical HF therapy and are also more prone to
experience adverse effects. Because the elderly also
have more comorbidities requiring speciﬁc therapies,
polypharmacy is commonplace. Medications with
opposing actions may be used simultaneously (e.g.,
inhaled beta-agonists, beta-blockers) such that med-
ications for non-HF comorbidities may exacerbate
HF and vice versa. In general, polypharmacy in-
creases the potential for drug interactions and re-
duces patients’ compliance. Moreover, frailty and
cognitive impairment are more common among
elderly HF patients and represent additional risks for
nonadherence.
Data on the speciﬁc role of polypharmacy in HFrEF
versus HFpEF are lacking. Given the greater burden of
comorbidities in HFpEF, it is reasonable to assume,
however, that the negative impact of polypharmacy is
at least as great in HFpEF compared with HFrEF. At
the same time, HF trials that established morbidity
and mortality beneﬁts were predominantly executed
in nonelderly cohorts. Assumption of similar efﬁcacy
in geriatric populations is mostly on the basis of
extrapolation of these data, but the true risk-beneﬁt
ratio may be less favorable.
These observations also may have important im-
plications for future HF trial design. As the clinical
trial landscape transitions toward more pragmatic
trials with broad entry criteria, in some circum-
stances, study populations may (and perhaps, should)
increasingly include those with multiple comorbid
diseases. Noncardiologists managing HF patients cite
comorbidity and lack of generalizability of previous
trials to comorbid patients as a “reason” for not
applying standard therapies. Improved generaliz-
ability of trial results could translate into increased
uptake of evidence-based treatments for both HF andcomorbid diseases. Although this approach may be
possible in HFrEF, given the heterogeneity of the
patient population, broad entry criteria for trials
in HFpEF might be more likely to fail. Strategies
to promote success include use of natriuretic pep-
tide levels for entry criteria, as highlighted by the
results of the recent TOPCAT (Treatment of Preserved
Cardiac Function Heart Failure With an Aldosterone
Antagonist) study (122). Importantly, data suggest
that the use of different threshold levels for natri-
uretic peptides may be appropriate in HFrEF versus
HFpEF patients, as well as in those with obesity
and renal dysfunction (123). Considerations for trial
design related to comorbidities are summarized in
Figure 1. Importantly, the inclusion of patients with
comorbidities in clinical trials may require intensiﬁed
monitoring and safety evaluations. For instance,
there are notable comorbidity-speciﬁc adverse effects
associated with certain medications (e.g., hyper-
kalemia with RAAS inhibition in renal dysfunction
patients). Finally, given the recent lack of success in
HF clinical trials using add-on HF-directed therapies
(e.g., direct renin inhibitors [124]), another potential
trial approach is to speciﬁcally target underlying
comorbidities to improve overall patient outcomes.
CONCLUSIONS
Compared with HFrEF, patients with HFpEF have an
increased burden of COPD, DM, anemia, and obesity
but a similarly high prevalence of renal disease and
SDB. In general, the increased risk for morbidity and
mortality associated with these comorbidities is
similar in those with HFpEF and HFrEF. Careful
attention to the diagnosis and management of spe-
ciﬁc comorbidities in HF patients may help to im-
prove patient outcomes, but further observational
and interventional research is urgently required,
particularly as noncardiac comorbidity is almost uni-
versal in the typical HF population.
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